The Effect of Lipoprotein-Associated Cyclosporine on Drug Metabolism and Toxicity in Rats

PDA Journal of Pharmaceutical Science and Technology

Volumn 57, Issue 6, 2003, Pages 410-424

  Kim, Taekrho ^a   Lu, Shirley K ^a   Brunner, Lane J ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 3A; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; SCAVENGER RECEPTOR; SODIUM CHLORIDE; VERY LOW DENSITY LIPOPROTEIN;

ANALYSIS OF VARIANCE; ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CATALYSIS; COMPARATIVE STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DISPOSITION; DRUG EFFECT; DRUG METABOLISM; DRUG UPTAKE; ENZYME ACTIVITY; GENE CONTROL; HUMAN; IMMUNOBLOTTING; KIDNEY FUNCTION; LIVER CELL; LIVER METABOLISM; LIVER MICROSOME; MALE; METABOLISM; NEPHROTOXICITY; NONHUMAN; RAT; RAT STRAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URINALYSIS;

ANALYSIS OF VARIANCE; ANIMALS; CYCLOSPORINE; HUMANS; LIPOPROTEINS; MALE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0346502240     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Borel, J. F.; Kis, Z. L. The discovery and development of cyclosporine (Sandimmune). Transplant Proc. 1991, 23(2), 1867.
2. Lopez-Miranda, J.; Blanco-Molina, A.; Lopez-Segura, F.; Nicolas-Puiggari, M.; Torre-Cisneros, J.; Perez-Jimenez, F. The effect of cyclosporine on exocrine function of the rat pancreas: An in vitro study. Transplantation 1991, 51(3), 562.
3. Luke, D. R.; Brunner, L. J.; Vadiei, K. Bioavailability assessment of cyclosporine in the rat: Influence of route of administration. Drug Metab. Dispos. 1990, 18, 158.
4. Mbewu, A.; Durrington, P. N. Lipoproteins involved in tissue repair. Atherosclerosis 1990, 85, 1.
5. Lemaire, M.; Tillement, J. P. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm. Pharmacol. 1982, 34, 715.
6. Niederberger, W.; Lemaire, M.; Maurer, G.; Nussbaumer, K.; Wagner, O. Distribution and binding of cyclosporine in blood and tissues. Transplant Proc. 1983, 15 (Suppl. 1), 2419.
7. Gurecki, J.; Warty, V.; Sanghvi, A. The transport of cyclosporine in association with plasma lipoproteins in heart and liver transplant patients. Transplant Proc. 1985, 17, 1997.
8. Ballantyne, C M.; Podet, E. J.; Patsch, W. P.; Harati, Y.; Appel, V.; Gotto, A. M. J.; Young, J. B. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989, 262(1), 53.
9. Ginsberg, H. N. Cyclosporine, plasma lipids, and organ transplantation. Hepatology 1996, 24(3), 735.
10. Verrill, H. L.; Girgis, R. E.; Easterling, R. E.; Malhi, B. S.; Mueller, W. F. Distribution of cyclosporine in blood of a renal-transplant recipient with type V hyperlipoproteinemia. Clin. Chem. 1987, 33(3), 423.
11. Dietschy, J. M. LDL cholesterol: Its regulation and manipulation. Hosp. Pract. 1990, 25(6), 67.
12. Kovanen, P. T.; Brown, M. S.; Goldstein, J. L. Increased binding of low density lipoprotein to liver membranes from rats treated with 17 alpha-ethinyl estradiol. J. Biol. Chem. 1979, 254(22), 11367.
13. Ma, P. T.; Yamamoto, T.; Goldstein, J. L.; Brown, M. S. Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17 alpha-ethinyl estradiol. Proc. Natl. Acad. Sci. 1986, 83(3), 792.
14. Parini, P.; Angelin, B.; Rudling, M. Importance of estrogen receptors in hepatic LDL receptor regulation. Arterioscler., Thromb. & Vasc. Biol. 1997, 17(9), 1800.
15. Srivastava, R. A. Regulation of the apolipoprotein E by dietary lipids occurs by transcriptional and post-transcriptional mechanisms. Mol. Cell Biochem. 1996, 155(2), 153.
16. Acton, S.; Rigotti, A.; Landschulz, K. T.; Xu, S.; Hobbs, H. H.; Krieger, M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271(5248), 518.
17. Glass, C.; Pittman, R.; Weinstein, D.; Steinberg, D. Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver adrenal, and gonad. Proc. Natl. Acad. Sci. 1983, 80, 5435.
18. Gupta, S.; Manfro, R.; Tomlanovich, S.; Gambertoglio, J.; Garovoy, M.; Benet, L. Effect of food on the pharmacokinetics of cyclosporine in health subjects following oral and intravenous administration. J. Clin. Pharmacol. 1990, 30, 643.
19. Rodl, S.; Fuchs, G.; Khoshsorur, G.; Iberer, F.; Tscheliessnigg, K. H. Lipoprotein-induced modulation of cyclosporine-A-mediated immunosuppression. Eur. J. Clin. Invest. 1990, 20, 248.
20. Gullberg, H.; Rudling, M.; Forrest, D.; Angelin, B.; Vennstrom, B. Thyroid hormone receptor beta-deficient mice show complete loss of the normal cholesterol 7alpha-hydroxylase (CYP7A) response to thyroid hormone but display enhanced resistance to dietary cholesterol. Mol. Endocrinol. 2000, 14(11), 1739.
21. Rodriguez, C.; Martinez-Gonzalez, J.; Sanchez-Gomez, S.; Badimon, L. LDL downregulates CYP51 in porcine vascular endothelial cells and in the arterial wall through a sterol regulatory element binding protein-2-dependent mechanism, Circ. Res. 2001, 88(3), 268.
22. Kronbach, T.; Fischer, V.; Meyer, U. A. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 1988, 43(6), 630.
23. Brunner, L. J.; Bennett, W. M.; Koop, D. R. Selective suppression of rat hepatic microsomal activity during chronic cyclosporine nephrotoxicity. J. Pharmcol. Exp. Ther. 1996, 277(3), 1710.
24. Elzinga, L. E.; Rosen, S.; Houghton, D. C. Chronic cyclosporine tubulointerstitial nephropathy with striped fibrosis: A rodent model. Proc. Am. Soc. Transplant Physicians 1989, A29.
25. Ferreri, L. Fractionation of plasma lipoproteins: Evaluation of preparative methods. In Laboratory and research methods in biology and medicine, Vol. 10; Story, J., Ed., Alan R. Liss, Inc.: New York, 1984; p 133.
26. Wasan, K. M.; Cassidy, S. M.; Ramaswamy, M.; Kennedy, A.; Strobel, F. W. ; Ng, S. P.; Lee, T. Y. A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine. Pharm. Res. 1999, 16(1), 165.
27. Chung, B. H.; Segrest, J. P.; Ray, M. J.; Brunzell, J. D.; Hokanson, J. E.; Krauss, R. M.; Beaudrie, K.; Cone, J. T. Single vertical spin density gradient ultracentrifugation. Methods Enzymol. 1986, 128, 181.
28. Sattler, W.; Mohr, D.; Stocker, R. Rapid isolation of lipoproteins and assessment of their peroxidation by high-performance liquid chromatography postcolumn chemiluminescence. Methods Enzymol. 1994, 233, 469.
29. Vega, G. L.; Grundy, S. M. Quantitation of apolipoprotein B by chemical methods. Methods Enzymol. 1996, 263(63), 63.
30. Converse, A.; Skinner, E. R. Lipoprotein Analysis: A Practical Approach. IRL Press/Oxford University Press: New York, 1992.
31. 4 (rabbit liver). Methods Enzymol. 1978, 52, 109.
32. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193, 265.
33. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227(259), 680.
34. Chomczynski, P.; Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162, 156.
35. Zhang, F.; Riley, J.; Gant, T. W. Use of internally controlled reverse transcriptase-polymerase chain reaction for absolute quantitation of individual multidrug resistant gene transcripts in tissue samples. Electrophoresis 1996, 17, 225.
36. Fukushima, M.; Nakano, M.; Morii, Y.; Ohashi, T.; Fujiwara, Y.; Sonoyama, K. Hepatic LDL receptor mRNA in rats is increased by dietary mushroom (Agaricus bisporus) fiber and sugar beet fiber. J. Nutr. 2000, 130(9), 2151.
37. Liang, K.; Vaziri, N. D. Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome Kidney Int. 1999, 56(2), 621.
38. Brunner, L. J.; Iyer, L. V.; Vadiei, K.; Weaver, W. V.; Luke, D. R. Cyclosporine pharmacokinetics and effect in the type I diabetic rat model Eur. J. Drug Metab. Pharmacokinet. 1989, 14(4), 287.
39. De Groen, P. C.; Aksamit, A. J.; Rakela, J.; Forbes, G. S.; Krom, R. A. Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. N. Engl. J. Med. 1987, 317(14), 861.
40. Luke, D. R.; Brunner, L. J.; Lopez-Berestein, G.; Yau, J. C. Pharmacokinetics of cyclosporine in bone marrow transplantation: Longitudinal characterization of drug in lipoprotein fractions. J. Pharm. Sci. 1992, 81(3), 208.
41. Nemunaitis, J.; Deeg, H. J.; Yee, G. C. High cyclosporine levels after bone marrow transplantaion associated with hypertriglyceridaemia. Lancet 1986, 2(8509), 744.
42. Yau, J. C.; Brunner, L. J.; Lopez-Berestein, G.; LeMaistre, C. F.; Luke, D. R. Therapeutic drug monitoring of cyclosporine-lipoprotein levels. Pharmacotherapy 1991, 11(4), 291.
43. Dorr, R. T. Pharmacology and toxicology of Cremophor EL diluent Ann. Pharmacother. 1994, 28, S11 (1994).
44. Goldspiel, B. R. Pharmaceutical issues: Preparation, administration, stability, and compatibility with other medications. Ann. Pharmacother. 1994, 28(5 Suppl), S23.
45. Kongshaug, M.; Cheng, L. S.; Moan, J.; Rimington, C. Interaction of Cremophor EL with human plasma. Int. J. Biochem. 1991, 23(4), 473.
46. Ramaswamy, M.; Zhang, X.; Burt, H. M.; Wasan, K. M. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J. Pharm. Sci. 1997, 86(4), 460.
47. Vitols, S. Uptake of low-density lipoprotein by malignant cells-possible therapeutic applications. Cancer Cells 1991, 3(12), 488.
48. Kaptein, A.; De Wit, E. C.; Princen, H. M. Co-translational inhibition of apoB-100 synthesis by cyclosporin A in the human hepatoma cell line HepG2. Arterioscler. Thromb. 1994, 14(5), 780.
49. De Groen, P. C. Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin. Proc. 1988, 63, 1012.
50. Mahley, R. W.; Innerarity, T. L.; Pitas, R. E.; Weisgraber, K. H.; Brown, J. H.; Gross, E. Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apolipoproteins. J. Biol. Chem. 1977, 252(20), 7279.
51. Lopez-Miranda, J.; Vilella, E.; Perez-Jimenez, F.; Espino, A.; Jimenez-Pereperez, J. A.; Masana, L.; Turner, P. R. Low-density lipoprotein metabolism in rats treated with cyclosporine. Metabolism 1993, 42(6), 678.
52. Myant, N. B. Choelsterol metabolism, LDL, and the LDL receptor. Academic Press, Inc.: San Diego, CA, 1990.